An App-based Instructional Platform to Improve Eye Drop Recall

December 22, 2025 updated by: University of California, San Francisco

Assessing the Effects of an In-office, Language-concordant App on Eye Drop Recall in Patients With Multi-drop Regimens

The goal of this interventional study is to assess whether an in-office, language-concordant instructional app improves drop regimen recall in a population of glaucoma patients who are on multi-drop regimens.

Participants will be divided into two groups -- those who use the app and those who do not. The app will have narrated information regarding the drop regimen, a quiz to test understanding of the regimen, and will enable a graphical printout of the eye drops and schedule.

At one month, both groups will be assessed on their eye drop regimen recall.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Specific Aim: To investigate whether a language-concordant instructional application improves drop regimen recall in population of glaucoma patients at a 1-month follow-up period.

App features

  1. Pictorial representation of drops (color-coded) and schedule.
  2. Quiz to assess understanding of the regimen.
  3. Narrated instructions (language-concordant) on how and when (frequency and eye laterality) to take each drop.
  4. Graphical print-out of the regimen.

Study design

  1. Study design: Randomized study, two groups: (1) patients that use the app, and (2) patients that do not use the app.

  2. Study population:

    Inclusion criteria: patients with primary open-angle glaucoma on at least 2 eye drops

    Exclusion criteria: patients taking additional prescribed eye drops for other eye conditions; patients diagnosed within the last 3 months; patients unable to self-administer eye drops

  3. Intervention: Use of an in-office app that has both graphical and verbal (language-concordant) instruction for how to use drops.
  4. Main outcome measure: Ability to correctly identify drops/regimen

Study Type

Interventional

Enrollment (Actual)

20

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • California
      • San Francisco, California, United States, 94110
        • San Francisco General Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • patients with a diagnosis of glaucoma (any type)
  • drop regimen of at least 2 pressure-lowering drops
  • languages supported at this time: English, Spanish, Cantonese

Exclusion Criteria:

  • concurrent eye conditions necessitating additional eye drops
  • inability to self-administer eye drops
  • inability to engage with app (either visual or other barrier)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: App arm
The intervention is an in-office app that contains graphical and narrated information on a patient's specific drop regimen, and includes a quiz and a graphical print-out of their drop schedule. The patient will use the app during their clinic visit.
Other: App

App features (App will be used during the office visit):

  • Pictorial representation of drops (color-coded) and schedule.
  • Quiz to assess understanding of the regimen.
  • Narrated instructions (language-concordant) on how and when (frequency and eye laterality) to take each drop.
  • Graphical print-out of the regimen.
Other Names:
  • App-based drop instructions
No Intervention: Standard arm
The standard arm will be the standard of care, which involves a provider explanation of their drop regimen (using a phone interpreter if needed).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage accuracy of drop regimen recall
Time Frame: 1 month follow up from time of intervention
This will be assessed through questions querying which drops the patients are taking, the number of times they are taking each drop, and the laterality of each drop. Each answer/drop will be individual recorded, and then total number of correct answers will be divided by the total number of questions.
1 month follow up from time of intervention

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Overall medication adherence, assessed through the modified Morisky Adherence Scale, a widely published scale for general medication adherence
Time Frame: 1 month follow up from time of intervention
An 8 question survey (7 questions are yes/no, with the final question on a Likert scale) gauging overall medication adherence. Each question will be individually assessed (not summed into a cumulative score). The higher number of "yes" responses corresponds to a lower adherence score.
1 month follow up from time of intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of California, San Francisco

Investigators

  • Principal Investigator: Frank Brodie, MD, UCSF, Department of Ophthalmology

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2024

Primary Completion (Actual)

June 1, 2025

Study Completion (Actual)

June 1, 2025

Study Registration Dates

First Submitted

September 13, 2023

First Submitted That Met QC Criteria

September 13, 2023

First Posted (Actual)

September 21, 2023

Study Record Updates

Last Update Posted (Actual)

December 30, 2025

Last Update Submitted That Met QC Criteria

December 22, 2025

Last Verified

December 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 23-39908

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe